Active, not recruitingInterventional · Phase 3NCT07169578 ↗A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)Sonja BlumPIInterventionDrug: Trontinemab · Other: PlaceboDatesSep 2025 – Feb 2028 (est.)SponsorF. Hoffman La-Roche LtdAlzheimers Disease